MedPath

Lomustine

Generic Name
Lomustine
Brand Names
Ceenu, Gleostine
Drug Type
Small Molecule
Chemical Formula
C9H16ClN3O2
CAS Number
13010-47-4
Unique Ingredient Identifier
7BRF0Z81KG
Background

An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication

For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions
Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
Clinical Trials
Related News

Procarbazine and Lomustine in Recurrent Glioblastoma

Phase 2
Conditions
Recurrent Glioblastoma Multiforme
Interventions
First Posted Date
2012-11-29
Last Posted Date
2012-12-03
Lead Sponsor
Incheon St.Mary's Hospital
Target Recruit Count
52
Registration Number
NCT01737346
Locations
🇰🇷

Ajou University Hospital, Wonchon-dong, Suwon, Korea, Republic of

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Phase 1
Completed
Conditions
Glioma
Interventions
First Posted Date
2012-09-10
Last Posted Date
2024-11-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
66
Registration Number
NCT01682187
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

A Study in Recurrent Glioblastoma (GB)

Phase 2
Completed
Conditions
Glioblastoma
Interventions
Drug: Placebo
First Posted Date
2012-04-20
Last Posted Date
2024-10-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
151
Registration Number
NCT01582269
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Phase 1
Terminated
Conditions
Leptomeningeal Metastasis From Malignant Melanoma
Interventions
Radiation: Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)
First Posted Date
2012-03-27
Last Posted Date
2016-04-19
Lead Sponsor
University Hospital, Bonn
Target Recruit Count
1
Registration Number
NCT01563614
Locations
🇩🇪

Neurologische Universitaetsklinik Bonn, Bonn, Germany

Bevacizumab and Lomustine for Recurrent GBM

Phase 3
Completed
Conditions
Glioblastoma Multiforme
Cognition Disorders
Disability Evaluation
Interventions
Biological: bevacizumab
Genetic: DNA methylation analysis
Other: laboratory biomarker analysis
Procedure: cognitive assessment
Procedure: quality-of-life assessment
First Posted Date
2011-02-07
Last Posted Date
2021-02-15
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
592
Registration Number
NCT01290939
Locations
🇳🇱

Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands

🇳🇱

Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Phase 2
Completed
Conditions
Brain Cancer
Glioblastoma
Interventions
First Posted Date
2010-02-11
Last Posted Date
2020-03-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
83
Registration Number
NCT01067469
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

Phase 2
Conditions
Primary Non Hodgkin Lymphoma of the Central Nervous System
First Posted Date
2009-10-05
Last Posted Date
2009-10-05
Lead Sponsor
University Hospital Freiburg
Target Recruit Count
56
Registration Number
NCT00989352
Locations
🇩🇪

University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology, Freiburg, Germany

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Phase 1
Terminated
Conditions
Glioblastoma
Interventions
First Posted Date
2009-07-29
Last Posted Date
2012-08-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
28
Registration Number
NCT00948389
Locations
🇨🇭

Local Institution, Lausanne, Switzerland

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Phase 3
Active, not recruiting
Conditions
Brain and Central Nervous System Tumors
Interventions
Radiation: radiotherapy
First Posted Date
2009-04-23
Last Posted Date
2024-08-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
305
Registration Number
NCT00887146
Locations
🇺🇸

Mount Carmel Health Center West, Columbus, Ohio, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 287 locations

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

Phase 3
Completed
Conditions
Recurrent Glioblastoma
Interventions
First Posted Date
2008-10-22
Last Posted Date
2016-12-28
Lead Sponsor
AstraZeneca
Target Recruit Count
423
Registration Number
NCT00777153
Locations
🇬🇧

Research Site, Sutton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy